Brokerages Set Definitive Healthcare Corp. (NASDAQ:DH) Price Target at $2.47

Shares of Definitive Healthcare Corp. (NASDAQ:DH) have been assigned an average rating of “Reduce” from the nine research firms that are currently covering the stock, Marketbeat reports. Four investment analysts have rated the stock with a sell rating, three have assigned a hold rating, one has assigned a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $2.4714.

DH has been the subject of several research analyst reports. Bank of America restated an “underperform” rating and issued a $0.70 target price on shares of Definitive Healthcare in a report on Monday, June 29th. Weiss Ratings reissued a “sell (e+)” rating on shares of Definitive Healthcare in a research report on Wednesday, June 3rd. Zacks Research upgraded Definitive Healthcare from a “strong sell” rating to a “hold” rating in a research report on Tuesday, April 28th. Robert W. Baird set a $1.10 target price on Definitive Healthcare in a report on Friday, May 8th. Finally, Wall Street Zen raised Definitive Healthcare from a “hold” rating to a “buy” rating in a research report on Sunday, July 26th.

Institutional Investors Weigh In On Definitive Healthcare

Several large investors have recently modified their holdings of DH. Goldman Sachs Group Inc. raised its position in Definitive Healthcare by 564.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 8,716,725 shares of the company’s stock valued at $25,191,000 after purchasing an additional 7,404,363 shares during the last quarter. Dimensional Fund Advisors LP grew its position in Definitive Healthcare by 1.6% during the 3rd quarter. Dimensional Fund Advisors LP now owns 2,073,197 shares of the company’s stock worth $8,417,000 after purchasing an additional 33,612 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its stake in Definitive Healthcare by 11.7% in the third quarter. Arrowstreet Capital Limited Partnership now owns 1,216,007 shares of the company’s stock valued at $4,937,000 after purchasing an additional 127,055 shares during the period. Bank of America Corp DE raised its holdings in shares of Definitive Healthcare by 23.7% in the second quarter. Bank of America Corp DE now owns 769,397 shares of the company’s stock valued at $3,001,000 after buying an additional 147,599 shares during the last quarter. Finally, Inspire Investing LLC boosted its stake in shares of Definitive Healthcare by 505.7% during the fourth quarter. Inspire Investing LLC now owns 698,967 shares of the company’s stock worth $2,006,000 after buying an additional 583,562 shares during the period. 98.67% of the stock is owned by institutional investors and hedge funds.

Definitive Healthcare Stock Down 4.9%

Shares of NASDAQ DH opened at $0.68 on Monday. Definitive Healthcare has a 1 year low of $0.62 and a 1 year high of $4.70. The company has a market capitalization of $72.00 million, a price-to-earnings ratio of -0.42, a price-to-earnings-growth ratio of 11.57 and a beta of 1.33. The company has a debt-to-equity ratio of 0.81, a current ratio of 1.75 and a quick ratio of 1.75. The business has a 50-day moving average of $0.80 and a two-hundred day moving average of $1.19.

Definitive Healthcare (NASDAQ:DH) last issued its earnings results on Thursday, May 7th. The company reported $0.06 earnings per share for the quarter, topping the consensus estimate of $0.03 by $0.03. The business had revenue of $55.93 million for the quarter, compared to analyst estimates of $55.02 million. Definitive Healthcare had a positive return on equity of 4.04% and a negative net margin of 76.04%.Definitive Healthcare has set its Q2 2026 guidance at 0.030-0.040 EPS and its FY 2026 guidance at 0.160-0.19 EPS. On average, analysts forecast that Definitive Healthcare will post 0.04 earnings per share for the current fiscal year.

Definitive Healthcare Company Profile

Definitive Healthcare (NASDAQ:DH) is a leading provider of intelligence and analytics on healthcare providers, organizations and the professionals who treat patients. Through its cloud-based platform, the company aggregates data from multiple sources—including claims, government registries, commercial filings and proprietary research—to deliver a unified view of the healthcare landscape. Its solutions enable life sciences companies, healthcare providers, payers and consulting firms to identify market opportunities, optimize sales and marketing efforts, improve operational efficiency and support better patient outcomes.

The company’s flagship offering is a subscription-based data platform that features detailed profiles on physicians, hospitals, health systems and post-acute care facilities.